Why Argenx’s broader Vyvgart label changes the treatment equation in generalized myasthenia gravis
Vyvgart now covers all adult gMG serotypes. Argenx gains a wider label, but payers and real-world durability remain the next test.
Pharma & Biotech
Pharma & Biotech
Viridian Therapeutics financing puts thyroid eye disease expansion strategy in sharper focus
Viridian has TED trial wins, but market entry needs capital. See why its $350m raise matters before commercialization.